Zevra Therapeutics (ZVRA) Capital Expenditures (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Capital Expenditures of $35000.0 for Q1 2026, up 212.9% on a QoQ basis from -$31000.0 in Q4 2025, and down 64.65% year-over-year from $99000.0 in Q1 2025.
Zevra Therapeutics (ZVRA) Capital Expenditures (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Capital Expenditures history runs 12 years deep, the most recent figure standing at $35000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 64.65% year-over-year to $35000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $771000.0 (up 678.79% YoY) and the FY2025 annual result came in at $835000.0, changed N/A from the prior year.
- Capital Expenditures was $35000.0 for Q1 2026 at Zevra Therapeutics, up from -$31000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $10.5 million in Q2 2022 and bottomed at -$10.5 million in Q1 2022.
- A 4-year average of $60000.0 and a median of $35000.0 in 2026 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 58327.78% in 2022, while the deepest fall reached 262250.0% in 2022.
- Zevra Therapeutics' Capital Expenditures stood at -$445000.0 in 2022, then soared by 116.18% to $72000.0 in 2023, then sank by 143.06% to -$31000.0 in 2025, then soared by 212.9% to $35000.0 in 2026.
- Business Quant data shows ZVRA's Capital Expenditures at $35000.0 in Q1 2026, -$31000.0 in Q4 2025, and $554000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,000.00 |
| Mar 31, 2026 | 35,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Sep 30, 2025 | 554,000.00 |
| Sep 30, 2025 | 554,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Sep 30, 2023 | 172,000.00 |
| Sep 30, 2023 | 172,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | -445,000.00 |
| Dec 31, 2022 | -445,000.00 |